139 related articles for article (PubMed ID: 27616199)
1. Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.
Zhang RR; Swanson KI; Hall LT; Weichert JP; Kuo JS
CNS Oncol; 2016 Oct; 5(4):223-31. PubMed ID: 27616199
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.
Swanson KI; Clark PA; Zhang RR; Kandela IK; Farhoud M; Weichert JP; Kuo JS
Neurosurgery; 2015 Feb; 76(2):115-23; discussion 123-4. PubMed ID: 25549194
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Jendrossek V; Hammersen K; Erdlenbruch B; Kugler W; Krügener R; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 2002 Jul; 50(1):71-9. PubMed ID: 12111115
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma multiforme fades on CT imaging after dexamethasone therapy.
Hasegawa H; Pal D; Ramirez R; Ismail A; Marks P
J Clin Neurosci; 2009 Dec; 16(12):1707-8. PubMed ID: 19766006
[TBL] [Abstract][Full Text] [Related]
5. The antineoplastic effect of methylprednisolone pulse therapy in two patients with glucocorticoid receptor-positive glioblastoma multiforme.
Ellemann K; Bollinger B; Soelberg Soerensen P; Zeeberg I
Acta Neurol Scand; 1988 Jan; 77(1):74-7. PubMed ID: 2833058
[TBL] [Abstract][Full Text] [Related]
6. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.
Weichert JP; Clark PA; Kandela IK; Vaccaro AM; Clarke W; Longino MA; Pinchuk AN; Farhoud M; Swanson KI; Floberg JM; Grudzinski J; Titz B; Traynor AM; Chen HE; Hall LT; Pazoles CJ; Pickhardt PJ; Kuo JS
Sci Transl Med; 2014 Jun; 6(240):240ra75. PubMed ID: 24920661
[TBL] [Abstract][Full Text] [Related]
7. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
8. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
9. SnapShot: glioblastoma multiforme.
Kotliarova S; Fine HA
Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
[No Abstract] [Full Text] [Related]
10. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
Bennett IE; Field KM; Hovens CM; Moffat BA; Rosenthal MA; Drummond K; Kaye AH; Morokoff AP
J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
[TBL] [Abstract][Full Text] [Related]
11. TSPO as a target for glioblastoma therapeutics.
Werry EL; Barron ML; Kassiou M
Biochem Soc Trans; 2015 Aug; 43(4):531-6. PubMed ID: 26551689
[TBL] [Abstract][Full Text] [Related]
12. The challenges associated with molecular targeted therapies for glioblastoma.
Jue TR; McDonald KL
J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
O'Neill AF; Qin L; Wen PY; de Groot JF; Van den Abbeele AD; Yap JT
J Neurooncol; 2016 Dec; 130(3):495-503. PubMed ID: 27576699
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of glioblastoma multiforme: an appraisal.
Batzdorf U
Bull Los Angeles Neurol Soc; 1966 Oct; 31(4):164-76. PubMed ID: 4292290
[No Abstract] [Full Text] [Related]
15. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
16. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.
Veeravagu A; Liu Z; Niu G; Chen K; Jia B; Cai W; Jin C; Hsu AR; Connolly AJ; Tse V; Wang F; Chen X
Clin Cancer Res; 2008 Nov; 14(22):7330-9. PubMed ID: 19010848
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of blood-brain barrier-stealth nanocomposites for in situ glioblastoma theranostics applications.
Su CH; Tsai CY; Tomanek B; Chen WY; Cheng FY
Nanoscale; 2016 Apr; 8(15):7866-70. PubMed ID: 27035391
[TBL] [Abstract][Full Text] [Related]
18. Possible role for furazolidone in the treatment of glioblastoma multiforme.
Karamanakos PN
J BUON; 2013; 18(4):1097. PubMed ID: 24344045
[No Abstract] [Full Text] [Related]
19. Invasion as target for therapy of glioblastoma multiforme.
Vehlow A; Cordes N
Biochim Biophys Acta; 2013 Dec; 1836(2):236-44. PubMed ID: 23891970
[TBL] [Abstract][Full Text] [Related]
20. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.
Corroyer-Dulmont A; Pérès EA; Gérault AN; Savina A; Bouquet F; Divoux D; Toutain J; Ibazizène M; MacKenzie ET; Barré L; Bernaudin M; Petit E; Valable S
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):682-94. PubMed ID: 26537287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
